RegulationMarketing Authorisation January 17, 2019 Janssen gets EC nod for prostate cancer drug Erleada By PBR Staff Writer Erleada is a next generation oral androgen receptor inhibitor approved to treat adult patients with nmCRPC who are at high risk of developing metastatic disease. Apalutamide holds capacity
Drug DiscoveryResearch & Development January 16, 2019 Sanofi to use Biomunex’s BiXAb platform to generate antibody therapeutics By PBR Staff Writer As part of the deal, Sanofi will use the BiXAb platform of Biomunex to generate and enhance bi-specific and multi-specific antibodies. Sanofi will take responsibility for the research,
Drug DiscoveryResearch & Development January 14, 2019 Charles River, Atomwise collaborate on AI-driven drug discovery By PBR Staff Writer Charles River said it is reaffirming the commitment to the future of drug discovery by advancing its integrated, innovative early-stage platform. As part of the deal, the partnership
RegulationDrug Filing January 11, 2019 Ocular seeks FDA nod for expanded indication of Dextenza eye treatment By PBR Staff Writer The company submitted a supplemental new drug application (sNDA) with the regulator for new indication of Dextenza. The FDA is expected to complete the review for new indication
Production & SalesManufacturing January 10, 2019 Takeda completes $62bn acquisition of Irish biotech firm Shire By PBR Staff Writer The cash-cum-stock deal between Takeda and Shire was signed in May 2018 in a move to create a global, values-based research and development (R&D) driven biopharma company headquartered
Production & SalesManufacturing January 8, 2019 Lilly to acquire Loxo Oncology for $8bn By PBR Staff Writer Loxo Oncology is engaged in the development and commercialization of highly selective drug candidates for patients with genomically defined cancers. The company is developing targeted drugs that are
Drug DiscoveryResearch & Development January 7, 2019 Sanofi to invest €80m in biopharmaceutical firm BioNTech By PBR Staff Writer BioNTech has expanded its research collaboration with Sanofi formed in late 2015 to advance the development of mRNA-based cancer immunotherapies. Simultaneously, BioNTech has signed an agreement with Sanofi
Production & SalesManufacturing January 4, 2019 Bristol-Myers Squibb to acquire Celgene for $74bn By PBR Staff Writer The merger of Bristol-Myers Squibb and Celgene is expected to result in a specialty biopharma company that will strive to develop high-value innovative medicines to meet the needs
Drug DiscoveryResearch & Development January 3, 2019 US cell therapies firm Promethera secures investment from ITOCHU By PBR Staff Writer ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is
Drug DiscoveryResearch & Development January 2, 2019 Clinical-stage biopharmaceutical firm Antengene completes $120m Series B financing By PBR Staff Writer Antengene has secured the money under series B financing round led by Boyu Capital and FountainVest. The participants include new investors such as Celgene, WuXi Corporate Venture Fund